Feasibility of placebo-controlled clinical trials of antipsychotic compounds in Europe

Psychopharmacology

Volumn 162, Issue 1, 2002, Pages 82-84

  Fleischhacker, Wolfgang W ^a   Burns, Tom ^b   European Group for Research in Schizophrenia, ^a  

^a UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Antipsychotic; Ethic; Placebo; Schizophrenia

Indexed keywords

NEUROLEPTIC AGENT; PLACEBO;

ARTICLE; ATTITUDE; CONTROLLED STUDY; ETHICS; EUROPE; FEASIBILITY STUDY; HEALTH CARE; HUMAN; MEDICAL RESEARCH; PRIORITY JOURNAL; QUESTIONNAIRE; REGULATORY MECHANISM; SCHIZOPHRENIA; CONTROLLED CLINICAL TRIAL; PSYCHOPHARMACOLOGY; STATISTICS;

ANTIPSYCHOTIC AGENTS; CONTROLLED CLINICAL TRIALS; EUROPE; FEASIBILITY STUDIES; HUMAN; PLACEBOS; PSYCHOPHARMACOLOGY; QUESTIONNAIRES; SUPPORT, NON-U.S. GOV'T; HUMANS;

EID: 0035987394     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-002-1060-z     Document Type: Article

References (8)

1. The rationale and ethics of medication-free research in schizophrenia
2. Clozapine dose in the United States and Europe: Implications for therapeutic and adverse effects
3. Medication-free research with schizophrenic patients
4. Placebo-controlled clinical trials: Patients' attitudes
5. The continuing unethical use of placebo controls
6. Schizophrenia: Do we really need placebo-controlled studies?
7. Placebo-controlled trials in schizophrenia: Are they ethical? Are they necessary?
8. Placebo-controlled studies in schizophrenia - Ethical and scientific perspectives: An overview of conference proceedings